MedTrace Logo

An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)

NCT00988832 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 380

Last updated 2015-09-02

Study results available
· View outcomes & findings →

Summary

The aim of this study is to quantify how infliximab therapy is being used in the UK and the consequent impact on health care resources, which will help to inform budget holders and payers on the costs associated with the treatment of Crohn's Disease.

Conditions

Interventions

BIOLOGICAL

Infliximab

Infliximab as prescribed by a physician in normal practice for Crohn's disease

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-12-31
Completion
2010-12-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00988832 on ClinicalTrials.gov